NXGL

Over the past six months, NexGel, Inc.'s stock price has declined significantly and experienced volatility. In April 2026, NexGel received a Nasdaq deficiency letter for failing to meet the minimum bid price requirement. Also in April 2026, NexGel closed the acquisition of Celularity's regenerative biomaterial products, financed by a $5.5 million investment from Sequence LifeScience. Approximately five months prior to May 2026, NexGel announced the spin-off of select drug delivery application assets into NexGelRx. In November 2025, NexGel reported flat Q3 2025 revenue but improved gross margin. For the full year 2025, revenue increased by 31.5%, but the company reported a net loss and acknowledged doubt about its ability to continue as a going concern. In late April 2026, Ian Blackman was appointed as CFO, and in early May 2026, Brian Kieser and Kevin Harris from Sequence LifeScience were appointed to the Board of Directors.